Tocilizumab

Generic Name: Tocilizumab

Brand Names: Actemra, RoActemra, Tyenne, Tofidence

Drug Type: Biotech

Chemical Formula: -

CAS Number: 375823-41-9

Unique Ingredient Identifier: I031V2H011

Background: Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 January 2010 to treat a number of inflamm...

Indication: Tocilizumab is indicated to treat moderate to severe rheumatoid arthritis, giant cell arteritis, systemic sclerosis-associated interstitial lung disease, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome.
...

Associated Conditions: Coronavirus Disease 2019 (COVID‑19), Cytokine Release Syndrome caused by CAR-T Cell Therapy, Giant Cell Arteritis (GCA), Juvenile Chronic Polyarthritis, Moderate to Severe Rheumatoid Arthritis, Moderately to Severely Active Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Systemic Juvenile Idiopathic Arthritis (SJIA), Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), Active systemic Juvenile idiopathic arthritis, Severe, active Rheumatoid arthritis

Associated Therapies: Monotherapy

Clinical Trials

A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Tocilizumab
Drug: DMARDs
Drug: Oral Corticosteroids
Drug: Methotrexate

First Posted Date: 2014-01-28

Last Posted Date: 2018-12-07

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 162

Registration Number: NCT02046603

Locations: 🇬🇧
Aberdeen Royal Infirmary, Aberdeen, United Kingdom
🇬🇧
Royal Sussex County Hospital; Clinical Investigation Research Unit, Brighton, United Kingdom
🇬🇧
University Hospital of Wales; Dept of Rhematology, Cardiff, United Kingdom

and more 35 locations

Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis

Phase 2

Completed

Conditions: Polymyositis
Dermatomyositis

Interventions: Drug: placebo
Drug: tocilizumab

First Posted Date: 2014-01-23

Last Posted Date: 2020-10-30

Lead Sponsor: Chester Oddis

Target Recruit Count: 36

Registration Number: NCT02043548

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
North Shore Long Island Jewish Center, Great Neck, New York, United States
🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States

and more 4 locations

Tocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia

Phase 4

Completed

Conditions: Schizophrenia
Schizoaffective Disorder

Interventions: Drug: Tocilizumab
Drug: Placebo

First Posted Date: 2014-01-13

Last Posted Date: 2018-12-26

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 59

Registration Number: NCT02034474

Locations: 🇺🇸
New York State Psychiatric Institute, New York, New York, United States

TOSCARA Study: A Study of Subcutaneous Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis Naïve to RoActemra/Actemra Treatment

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: tocilizumab

First Posted Date: 2014-01-09

Last Posted Date: 2017-08-01

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 57

Registration Number: NCT02031471

Tocilizumab and Hemophagocytic Lymphohistiocytosis (HLH)

Phase 2

Withdrawn

Conditions: Hemophagocytic Lymphohistiocytosis

Interventions: Drug: tocilizumab

First Posted Date: 2013-12-10

Last Posted Date: 2022-03-28

Lead Sponsor: Children's Hospital of Philadelphia

Registration Number: NCT02007239

Locations: 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

A Study of Tocilizumab (RoActemra) in Tocilizumab-Naive Participants With Rheumatoid Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) and/or Biologic Therapy

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Tocilizumab
Drug: Methotrexate
Drug: csDMARDs

First Posted Date: 2013-12-05

Last Posted Date: 2018-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 139

Registration Number: NCT02001987

A Study on Safety and Efficacy of Tocilizumab (RoActemra/Actemra) Alone or in Combination With Non-Biologic Antirheumatics in Participants With Rheumatoid Arthritis

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Non-Biologic DMARDs
Drug: Tocilizumab
Drug: Methotrexate

First Posted Date: 2013-11-19

Last Posted Date: 2017-06-19

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 150

Registration Number: NCT01987479

Locations: 🇳🇱
Gelre Ziekenhuizen; Reumatologie, Apeldoorn, Netherlands
🇳🇱
Antonius Ziekenhuis Sneek; Department of Rheumatology, Sneek, Netherlands
🇳🇱
Amphia ziekenhuis, locatie langendijk, Breda, Netherlands

and more 17 locations

An Open-Label Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Tocilizumab

First Posted Date: 2013-09-26

Last Posted Date: 2016-09-21

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 52

Registration Number: NCT01951170

A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Azathioprine
Drug: Chloroquine
Drug: Hydroxychloroquine
Drug: Leflunomide
Drug: Methotrexate
Drug: Sulfasalazine
Drug: Tocilizumab

First Posted Date: 2013-09-13

Last Posted Date: 2018-11-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 100

Registration Number: NCT01941095

Locations: 🇬🇷
Laiko General Hospital; Dept. of Pathophysiology-Uni of Athens, Athens, Greece
🇬🇷
Uni Hospital of Ioannina; Rheumatology, Ioannina, Greece
🇬🇷
General Hospital of Thessaloniki HIPPOKRATIO; Clinical Immunology Unit,2nd Dept of Internal Medicine, Thessaloniki, Greece

and more 7 locations

A Study to Evaluate Efficacy of Tocilizumab Administered as Monotherapy or in Combination With Methotrexate and/or Other Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis (RA) Participants

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Tocilizumab
Drug: DMARDs

First Posted Date: 2013-09-13

Last Posted Date: 2017-07-11

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 227

Registration Number: NCT01941940

Locations: 🇮🇹
Osp S. Maria Misericordia Dip. Medicina Clinica Sperimentale Cattedra Reumatologia, Perugia, Umbria, Italy
🇮🇹
Uni Degli Studi Di L Aquila; Cattedra Di Reumatologia - Dept. Di Medicina Interna E San, Coppito, Abruzzo, Italy
🇮🇹
Ospedale Regionale Torrette; SOD Clinica Medica del Dipartimento di Medicina Interna e Specialisti, Ancona, Marche, Italy

and more 46 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy